Phase I Study of Topical CRx-191 in Normal Healthy Volunteers
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
CRx-191 is a proprietary synergistic combination drug candidate being evaluated by
CombinatoRx for topical psoriasis therapy. CRx-191 was identified via a proprietary screening
assay for novel drug combinations demonstrating enhanced inhibition of tumor necrosis factor-
alpha and interferon-gamma release, cytokines that are implicated in the pathogenesis of
psoriasis.